Drug facts
MoleculeFluticasone and Salmeterol (Advair HFA)
Generics already compete: 5 makers on the market. 14 A-rated products from 5 makers substitute at the counter.
Advair Diskus 100/50 was first approved by the FDA on 08/24/2000 under NDA 021077; the application holder is Glaxo Group Ltd England Dba Glaxosmithkline.
The latest NADAC for FLUTICASONE-SALMETEROL 500-50 is $1.62 per unit (as of 10/28/2026).
Holder Glaxo Group Ltd England Dba GlaxosmithklineApplication NDA 021077Approved 08/24/2000
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
- Latest patent
- No Advair Diskus 100/50 patent listed in the Orange Book Orange Book
- Later patents, other products
- Airduo Digihaler 01/06/2041 Orange Book
02Competition
- Generics
- 5 generic makers Orange Book
- First generic approved
- 01/30/2019 Orange Book
Every listingEach listing and maker behind the generics count.
Price erosionHow NADAC moves as generics enter.
PrescribersWho prescribes it, from Medicare data.
Available in the full Fluticasone and Salmeterol profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
- NADAC
- $1.62 per unitFLUTICASONE-SALMETEROL 500-50, mid-priced of 6 strengths, as of 10/28/2026 CMS NADAC
- Latest recall
- 01/26/2022Class II, Fluticasone Propionate and Salmeterol, Cardinal Healthcare FDA enforcement
04Product
- Application holder
- Glaxo Group Ltd England Dba Glaxosmithkline Orange Book
- Application
- NDA 021077 Orange Book
- First approved
- 08/24/2000 Orange Book
- Dosage forms
- aerosol, metered; powder
- Routes
- inhalation
- Other brand names
- Advair Diskus 100/50Advair Diskus 250/50Advair Diskus 500/50Airduo RespiclickWixela Inhub
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.